Gilead presents additional efficacy, safety and demographic data from PURPOSE 2 trial at 5th HIV Research for Prevention Conference
FOSTER CITY, Calif., October 07, 2024 — Gilead Sciences, Inc. (Nasdaq: GILD) today announced additional data from its pivotal Phase 3 PURPOSE 2 trial (NCT04925752) providing an overview of the efficacy and safety of twice-yearly lenacapavir, the company’s injectable HIV-1 capsid inhibitor, for the investigational use of HIV prevention among a broad and geographically diverse range of cisgender men and gender-diverse people.
The new data are being presented during an oral abstract session on October 8 at the 5th HIV Research for Prevention Conference (HIVR4P) in Lima, Peru and follow the unblinding of the trial at interim analysis in September, which showed that twice-yearly lenacapavir reduced HIV infections by 96% compared to background HIV incidence (bHIV) and demonstrated superiority to once-daily Truvada® (emtricitabine 200 mg and tenofovir disoproxil fumarate 300 mg; F/TDF) for HIV prevention as pre-exposure prophylaxis (PrEP).
Read the full press release here.
SEE ALSO:
Source : Gilead Sciences, Inc.
Related HIV and Co-Infections News
-
[CROI 2026] HIV i-Base: Only three new HIV cases on lenacapavir PrEP: updates from PURPOSE-1 and -2
-
aidsmap: DoxyPEP halves overall syphilis cases, with possible indirect benefits for women
-
[Press release] US and Global Fund expand commitment to long-acting HIV prevention as country rollout of lenacapavir accelerates
Get involved
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Subscribe
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.